CN Patent

CN102098917A — 作为激酶抑制剂化合物的取代的哒嗪羧酰胺化合物

Assigned to Betta Pharmaceuticals Co Ltd · Expires 2011-06-15 · 15y expired

What this patent protects

本发明涉及一种哒嗪衍生物，其具有作为蛋白激酶抑制剂的意外的药物性质并且可用于治疗与异常蛋白激酶活性相关的紊乱，诸如癌症。

USPTO Abstract

本发明涉及一种哒嗪衍生物，其具有作为蛋白激酶抑制剂的意外的药物性质并且可用于治疗与异常蛋白激酶活性相关的紊乱，诸如癌症。

Drugs covered by this patent

ensartinib-hydrochloride (ENSARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN102098917A
Jurisdiction: CN
Classification: —
Expires: 2011-06-15
Drug substance claim: No
Drug product claim: No
Assignee: Betta Pharmaceuticals Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.